 ATLANTA, GA, March 18, 2020 GLOBE NEWSWIRE -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. GOVX, a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today provided an update on its development of a vaccine for preventioncontrol of novel coronavirus disease COVID-19 caused by SARS-Cov-2 coronavirus. GeoVax is using its GV-MVA-VLPTM vaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the virus responsible for the ongoing COVID-19 outbreak originating in Wuhan, China. 